Carbonic anhydrase 5B, mitochondrial
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Carbonic anhydrase 5B, mitochondrial as ChEMBL target CHEMBL3969, mapped to UniProt Q9Y2D0. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Carbonic anhydrase 5B, mitochondrial matters
Carbonic anhydrase 5B, mitochondrial is reviewed as Carbonic anhydrase 5B, mitochondrial (UniProt Q9Y2D0); the current evidence base includes 27 approved drugs, 746 compounds, and 84 assays, with lead potency reaching pChEMBL 11.0.
Carbonic anhydrase 5B, mitochondrial Sequence length is 317 aa.
Review this target as Carbonic anhydrase 5B, mitochondrial, mapped to UniProt Q9Y2D0. Sequence length is 317 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 27 approved drugs, 746 compounds, and 84 assays for this target. The dominant activity type is KI. CHEMBL4446052 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL4446052 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Carbonic anhydrase 5B, mitochondrial matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q9Y2D0, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4446052
|
11.0 | Kd | — |
|
|
No preferred name
CHEMBL4444784
|
11.0 | Kd | — |
|
|
No preferred name
CHEMBL4555586
|
11.0 | Kd | — |
|
|
No preferred name
CHEMBL4555622
|
11.0 | Kd | — |
|
|
No preferred name
CHEMBL4463683
|
10.9 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LACOSAMIDE
CHEMBL58323
|
2008 |
|
|
VALDECOXIB
CHEMBL865
|
2001 |
|
|
BRINZOLAMIDE
CHEMBL220491
|
1998 |
|
|
CELECOXIB
CHEMBL118
|
1998 |
|
|
TOPIRAMATE
CHEMBL220492
|
1996 |
|
|
DORZOLAMIDE
CHEMBL218490
|
1994 |
|
|
INDAPAMIDE
CHEMBL406
|
1983 |
|
|
ETHOXZOLAMIDE
CHEMBL18
|
1982 |
|
|
DOBUTAMINE
CHEMBL926
|
1978 |
|
|
FUROSEMIDE
CHEMBL35
|
1966 |
|
|
CHLORTHALIDONE
CHEMBL1055
|
1960 |
|
|
TRICHLORMETHIAZIDE
CHEMBL1054
|
1960 |
|
|
METHAZOLAMIDE
CHEMBL19
|
1959 |
|
|
DICHLORPHENAMIDE
CHEMBL17
|
1958 |
|
|
ACETAZOLAMIDE
CHEMBL20
|
1953 |